Clearance time and effective patent term in medical devices: evidence from EU and US records

In the world of medical innovation, a new device is not truly valuable until it can reach the patient. To get there, it must pass through a gatekeeper: a regulatory review that checks whether the invention is safe and effective. This process takes time, and for the companies that build these devices, time is a currency they cannot afford to lose. Every medical device is usually protected by a patent, a legal right that gives the creator a limited window—often twenty years—to sell the product and recoup their investment. However, this clock starts ticking the moment the patent is filed, long before the device ever sees a doctor or a hospital. While the company waits for regulators to say "yes," the patent continues to run down. If the wait is too long, or if the wait is too unpredictable, the company may find that by the time they are finally allowed to sell, their exclusive right to profit has already expired. This is the hidden cost of bureaucracy: it does not just delay a product; it eats away at the very asset the company was trying to protect.

This reality creates a difficult puzzle for inventors, especially small and medium-sized businesses that do not have deep pockets to survive long delays. They must decide whether to seek approval in Europe or the United States first, or perhaps try both at once. The choice depends on how long the review will take and how certain that timeline is. A predictable delay is manageable; a wild, uncertain wait can bankrupt a project. Until now, most discussions about these delays focused only on the average time it takes to get approved. But averages can be misleading. A process that usually takes a year but occasionally drags on for five years is far more dangerous to a small business than a process that always takes exactly two years, even if the average is the same. The danger lies in the "tail" of the distribution—the rare, extreme delays that can push a company past its financial breaking point.

A recent study by Andreas Peters, a researcher at Rosenheim Technical University of Applied Sciences, sets out to measure exactly how much of a patent's life is consumed by these regulatory waits in Europe and the United States. The research does not just look at the average wait time; it maps out the entire range of possibilities, from the fastest approvals to the slowest, and examines how these delays affect companies of different sizes. By analyzing thousands of real-world records from the US Food and Drug Administration and survey data from European regulators, the study reveals a stark difference between the two sides of the Atlantic. It shows that the European route, under its current rules, consumes significantly more of a company's patent life than the American route. More importantly, it finds that the European system is far less predictable, creating a hidden risk that falls hardest on smaller manufacturers who cannot afford to wait.

The study begins by comparing the two main pathways for getting a medical device approved. In the United States, there are different tracks depending on the risk of the device. For moderate-risk devices, the "510(k)" process is relatively quick, taking an average of about five and a half months. For the highest-risk devices, the "premarket approval" process takes longer, averaging nearly fifteen months. In Europe, under the Medical Devices Regulation, the process is much slower. The study finds that getting a certificate in Europe takes, on average, between eighteen and twenty-two months. This means that for a moderate-risk device, the European route eats up about one to one and a half years more of the patent's life than the standard American route. For high-risk devices, the gap is smaller but still present, as the American high-risk process is also quite lengthy.

However, the average is only half the story. The study digs deeper into the uncertainty of these timelines. In the United States, the researchers were able to look at every single application file, allowing them to see the full picture of how long approvals actually took. They found that while most 510(k) applications are cleared quickly, about one in ten takes longer than ten months. For the most complex, high-risk approvals, one in ten takes longer than twenty-seven months. In Europe, the data is less detailed. Regulators do not publish the timeline for every single application; instead, they report ranges based on surveys of the organizations that do the reviewing. Even with this limited data, the picture is clear: the European process has a much longer "tail." The study estimates that for European certifications, the ninety percent of cases that take the longest can stretch well beyond two years, with no clear upper limit in the data. This unpredictability is a major problem for companies trying to plan their finances.

The consequences of this uncertainty are not felt equally by all companies. The research highlights a significant divide between large corporations and small and medium-sized enterprises. While the average wait time for a small company is not drastically longer than for a large one, the worst-case scenarios are much worse for the small players. The study finds that half of the small manufacturers reported that their technical documentation reviews took longer than fifteen months, compared to only a quarter of large manufacturers. When looking at the slowest ten percent of cases, the difference is even more dramatic: the ninety percent mark for small companies sits at thirty-four months, while for large companies it is just under twenty months. This means that a small company is far more likely to hit a multi-year delay that could exhaust its funding. Furthermore, the fixed costs of these reviews are a much heavier burden for small firms. The fees required to get certified can equal nearly a third of a small company's annual revenue, whereas for a larger firm, the same fees are a tiny fraction of their income.

The study also explores the strategic choices companies face. If a company wants to sell in both Europe and the United States, should it apply to one region first? The analysis suggests that for most companies, applying to the United States first is not the best strategy unless they can use the time spent waiting for the US decision to significantly speed up their European application. The math shows that for a company to make the US-first approach worthwhile, it would need to save between two and five and a half months on the European process by preparing the file while waiting for the US decision. This is a very high bar. The study notes that the difference in speed between small and large companies in Europe is roughly five months, suggesting that only the most experienced or well-resourced firms might benefit from this strategy. For everyone else, applying in parallel or focusing on the European market first might be the only viable option, despite the longer wait.

One of the most critical findings of the paper is that the current way of reporting regulatory times hides the true risk. In Europe, regulators often report the median time, which is the middle point where half the cases are faster and half are slower. This number looks reasonable, but it tells companies nothing about the extreme delays that can happen at the end of the line. The study argues that this lack of transparency is dangerous. Because the data does not show the upper limits of the wait times, investors and lenders cannot accurately assess the risk of funding a medical device project. They might think the wait is manageable based on the average, only to find out later that the project is stuck in a queue for years. The paper suggests that regulators should start reporting the ninety percent mark—the time by which ninety percent of applications are cleared—so that companies and investors can see the worst-case scenarios.

The research also points out that the United States has a safety net that Europe lacks. In the US, if a device goes through a long regulatory review, the patent office can grant an extension to the patent term to make up for the time lost. This is a crucial mechanism that helps protect the value of the invention. In Europe, no such mechanism exists for medical devices. Every month spent waiting in the European queue is a month of patent protection that is lost forever. This asymmetry makes the European system even more punishing for innovators, particularly those who cannot afford to lose time.

Ultimately, the study paints a picture of a regulatory environment where the rules are the same for everyone on paper, but the experience is vastly different in reality. The system is built on a finite pool of reviewers who must handle devices of varying complexity. When a small company with a less complete application file enters this queue, it often gets stuck behind more complex cases or requires multiple rounds of corrections, pushing its wait time into the dangerous tail of the distribution. Large companies, with their experienced regulatory teams and complete files, tend to move through the system more smoothly. The study concludes that simply measuring the average time is not enough. To truly understand the burden of regulation, we must look at the spread of times and the risks at the extremes. For the future of medical innovation, especially for the small companies that drive much of the creativity in the field, the solution lies not just in speeding up the process, but in making the timeline predictable and transparent, so that no one is left waiting in the dark.